These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 19570819)

  • 1. Dose-dependent melanonychia by mitoxantrone.
    Reinsberger C; Meuth SG; Wiendl H
    Mult Scler; 2009 Sep; 15(9):1131-2. PubMed ID: 19570819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.
    Sadiq SA; Rammal M; Sara G
    Mult Scler; 2008 Mar; 14(2):272-3. PubMed ID: 17986509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
    Vollmer T; Panitch H; Bar-Or A; Dunn J; Freedman MS; Gazda SK; Campagnolo D; Deutsch F; Arnold DL
    Mult Scler; 2008 Jun; 14(5):663-70. PubMed ID: 18424479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mitoxantrone].
    Pericot I; Montalban X
    Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mitoxantrone for the treatment of patients with multiple sclerosis].
    Komori M; Kondo T; Tanaka M
    Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone (Novantrone) in multiple sclerosis: new insights.
    Neuhaus O; Kieseier BC; Hartung HP
    Expert Rev Neurother; 2004 Jan; 4(1):17-26. PubMed ID: 15853611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nursing care of patients with basic multiple sclerosis therapy: preventing relapses].
    Balzer K
    Pflege Z; 2007 Dec; 60(12):662-3. PubMed ID: 18200980
    [No Abstract]   [Full Text] [Related]  

  • 8. Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis.
    Cursiefen S; Flachenecker P; Toyka KV; Rieckmann P
    Eur Neurol; 2000; 43(3):186-7. PubMed ID: 10765063
    [No Abstract]   [Full Text] [Related]  

  • 9. Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
    Hamzehloo A; Etemadifar M
    Arch Iran Med; 2006 Apr; 9(2):111-4. PubMed ID: 16649351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukaemia due to mitoxantrone.
    Prescrire Int; 2007 Aug; 16(90):153-6. PubMed ID: 17724842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nail pigmentation due to hydroxycarbamide.
    Ceulen RP; Frank J; Poblete-Gutiérrez P
    Int J Dermatol; 2007 Nov; 46 Suppl 3():13-5. PubMed ID: 17973880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis].
    Feuillet L; Guedj E; Eusebio A; Malikova I; Pelletier J; Mundler O; Ali Chérif A;
    Rev Neurol (Paris); 2003 Dec; 159(12):1169-72. PubMed ID: 14978418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
    Ellis R; Brown S; Boggild M
    Mult Scler; 2015 Apr; 21(5):642-5. PubMed ID: 25013152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and acceptance of prolonged low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis.
    Zecca C; Petrini L; Limoni C; Staedler C; Gobbi C
    Eur Neurol; 2011; 65(1):40-5. PubMed ID: 21196739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Longitudinal melanonychia and hydroxyurea].
    Pirard C; Michaux JL; Bourlond A
    Ann Dermatol Venereol; 1994; 121(2):106-9. PubMed ID: 7979014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic role of mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Pharmacol Ther; 2006 Jan; 109(1-2):198-209. PubMed ID: 16095713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.
    Wundes A; Kraft GH; Bowen JD; Gooley TA; Nash RA
    Clin Neurol Neurosurg; 2010 Dec; 112(10):876-82. PubMed ID: 20727669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.
    Ramkumar B; Chadha MK; Barcos M; Sait SN; Heyman MR; Baer MR
    Cancer Genet Cytogenet; 2008 Apr; 182(2):126-9. PubMed ID: 18406875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nail pigmentation caused by hydroxyurea: report of 9 cases.
    Aste N; Fumo G; Contu F; Aste N; Biggio P
    J Am Acad Dermatol; 2002 Jul; 47(1):146-7. PubMed ID: 12077597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide-induced nail discoloration and skin hyperpigmentation: a rare presentation.
    Chittari K; Tagboto S; Tan BB
    Clin Exp Dermatol; 2009 Apr; 34(3):405-6. PubMed ID: 18627381
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.